🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Small Bowel Adenocarcinoma

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors NCT06835387Phase 27 sites📍 Tampa📍 Chicago📍 Fort Wayne Tiago Biachi de Castria · Tests: Nanoliposomal irinotecan, Oxaliplatin, 5 fluorouracil, Leucovorin Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies NCT04282044Phase 13 sites📍 Scottsdale📍 La Jolla📍 Stanford BioEclipse Therapeutics · Tests: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide TT-702 in Patients With Advanced Solid Tumours. NCT05272709Phase 1, Phase 23 sites📍 London📍 Manchester📍 Southampton Cancer Research UK · Tests: TT-702, Anti-PD-1 and PD-L1 agent KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors NCT06026410Phase 138 sites📍 Phoenix📍 Tucson📍 Los Angeles Kura Oncology, Inc. · Tests: Darlifarnib, Cabozantinib, Adagrasib AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors NCT07094113Phase 139 sites📍 Duarte📍 Los Angeles📍 Atlanta Amgen · Tests: AMG 410, Pembrolizumab, Panitumumab 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors NCT07557225NA1 site📍 Beijing Peking University First Hospital · Tests: 18F-T2 PET/CT A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors NCT07749586Phase 1, Phase 24 sites📍 New York📍 Huntersville📍 San Antonio Arvinas Inc. · Tests: ARV-6723, Pembrolizumab, SOC Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors NCT05969041Phase 16 sites📍 Darlinghurst📍 Randwick📍 Westmead Myeloid Therapeutics · Tests: MT-302 (A) A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840Phase 148 sites📍 Phoenix📍 Scottsdale📍 Duarte Seagen, a wholly owned subsidiary of Pfizer · Tests: PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV) Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981Phase 17 sites📍 Detroit📍 St Louis📍 Canton Sairopa B.V. · Tests: ADU-1805, Pembrolizumab Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) NCT07795749Phase 21 site📍 Orange University of California, Irvine · Tests: Paclitaxel Q2W, Paclitaxcel Q3W A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors NCT07376707Phase 11 site📍 Shanghai Hefei TG ImmunoPharma Co., Ltd. · Tests: TGI-5 Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors NCT06040541Phase 117 sites📍 Sacramento📍 New Haven📍 Sarasota Revolution Medicines, Inc. · Tests: RMC-9805, RMC-6236 Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT05379985Phase 1, Phase 221 sites📍 Orange📍 Santa Monica📍 Tampa Revolution Medicines, Inc. · Tests: RMC-6236 A Study of IBI363 in Subjects with Advanced Solid Malignancies NCT06281678Phase 29 sites📍 San Francisco📍 Ocala📍 Plantation Innovent Biologics (Suzhou) Co. Ltd. · Tests: IBI363 Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors NCT07334119Phase 17 sites📍 Darlinghurst📍 Randwick📍 Waratah Myeloid Therapeutics · Tests: MT-304, MT-304 + Nivolumab Small Bowel Capsule Endoscopy in Lynch Syndrome NCT07472686n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors NCT07229313Phase 17 sites📍 Santa Monica📍 New Have📍 Camperdown Kivu Bioscience Inc. · Tests: KIVU-107 A Multicenter Cancer Biospecimen Collection Study NCT04510129n/a1 site📍 San Francisco Cofactor Genomics, Inc. · Tests: OncoPrism™ assay Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. NCT07148128Phase 1, Phase 24 sites📍 Dallas📍 San Antonio📍 Toronto Auricula Biosciences Inc. · Tests: WEF-001 Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) NCT06101277NA1 site📍 Sacramento University of California, Davis · Tests: Ablative local therapy Development and Dissemination of Exercise Prescription and Intervention for Cancer Populations NCT07751783NA1 site📍 Kaohsiung Kaohsiung Medical University Chung-Ho Memorial Hospital · Tests: structured exercise training Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors NCT06239194Phase 1, Phase 26 sites📍 Denver📍 Miami📍 Boston ModeX Therapeutics, An OPKO Health Company · Tests: MDX2001 A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors NCT07094204Phase 120 sites📍 Santa Monica📍 Atlanta📍 Jefferson Astellas Pharma Inc · Tests: ASP5834, panitumumab A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations NCT06835569Phase 114 sites📍 Orlando📍 Tampa📍 Boston Alterome Therapeutics, Inc. · Tests: ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations NCT07629960Phase 1, Phase 216 sites📍 Sarasota📍 Tampa📍 Baton Rouge Blueprint Medicines Corporation · Tests: BLU-924 The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors NCT05037825n/a1 site📍 Elizabethtown VastBiome · Tests: Checkpoint Inhibitor, Immune Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care NCT06234306n/a3 sites📍 Aarhus N📍 Copenhagen Ø📍 Herlev Copenhagen University Hospital at Herlev A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer NCT07227168Phase 19 sites📍 San Diego📍 Denver📍 Washington D.C. Sutro Biopharma, Inc. · Tests: STRO-004, Pembrolizumab A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites📍 Sacramento📍 Celebration📍 Miami Marengo Therapeutics, Inc. · Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy